Cargando…

Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines

Several effective SARS-CoV-2 vaccines have been developed using different technologies. Although these vaccines target the isolates collected early in the pandemic, many have protected against serious illness from newer variants. Nevertheless, efficacy has diminished against successive variants and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scaria, Puthupparampil V., Rowe, Chris G., Chen, Beth B., Dickey, Thayne H., Renn, Jonathan P., Lambert, Lynn E., Barnafo, Emma K., Rausch, Kelly M., Tolia, Niraj H., Duffy, Patrick E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270177/ https://www.ncbi.nlm.nih.gov/pubmed/35846379 http://dx.doi.org/10.1016/j.isci.2022.104739

Ejemplares similares

Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity
por: Scaria, Puthupparampil V., et al.
Publicado: (2017)

Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response
por: Dickey, Thayne H., et al.
Publicado: (2022)

Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques
por: Scaria, Puthupparampil V., et al.
Publicado: (2021)

Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230
por: Scaria, Puthupparampil V., et al.
Publicado: (2019)

Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines
por: Dickey, Thayne H., et al.
Publicado: (2023)

A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle
por: Salinas, Nichole D., et al.
Publicado: (2023)

Design of a stabilized non-glycosylated Pfs48/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine
por: Dickey, Thayne H., et al.
Publicado: (2023)

Structure-based design of a strain transcending AMA1-RON2L malaria vaccine
por: Patel, Palak N., et al.
Publicado: (2023)

The Immunogenicity of Peptoid-Protein Conjugates
por: Case, Allison, et al.
Publicado: (2016)

The telomeric protein Pot1 from Schizosaccharomyces pombe binds ssDNA in two modes with differing 3′ end availability
por: Dickey, Thayne H., et al.
Publicado: (2014)

Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate
por: Radtke, Andrea J., et al.
Publicado: (2017)

Immunogenicity of Self-Associated Aggregates and Chemically Cross-Linked Conjugates of the 42 kDa Plasmodium falciparum Merozoite Surface Protein-1
por: Qian, Feng, et al.
Publicado: (2012)

Protein-based antigen presentation platforms for nanoparticle vaccines
por: Nguyen, Brian, et al.
Publicado: (2021)

Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion
por: Patel, Palak N., et al.
Publicado: (2022)

Structural basis for placental malaria mediated by Plasmodium falciparum VAR2CSA
por: Ma, Rui, et al.
Publicado: (2021)

Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein
por: Dormeshkin, Dmitri, et al.
Publicado: (2023)

Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice
por: Healy, Sara A., et al.
Publicado: (2021)

Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
por: Sun, Shiyu, et al.
Publicado: (2021)

Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae
por: Turner, Allison E.B., et al.
Publicado: (2017)

Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2
por: Leal, Lorna, et al.
Publicado: (2023)

Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential vaccine against SARS-CoV-2
por: Moshref Javadi, Mahtab, et al.
Publicado: (2022)

A Method for Producing Protein Nanoparticles with Applications in Vaccines
por: Jones, David S., et al.
Publicado: (2016)

Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission
por: Rausch, Kelly M., et al.
Publicado: (2023)

Enhancing the Immunogenicity of RBD Protein Variants through Amino Acid E484 Mutation in SARS-CoV-2
por: Zhang, Zhikai, et al.
Publicado: (2022)

The SMAD3 transcription factor binds complex RNA structures with high affinity
por: Dickey, Thayne H., et al.
Publicado: (2017)

Author Correction: Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2
por: Sun, Shiyu, et al.
Publicado: (2021)

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
por: Tai, Wanbo, et al.
Publicado: (2020)

A Polysaccharide-RBD-Fc-Conjugated COVID-19 Vaccine, SCTV01A, Showed High Immunogenicity and Low Toxicity in Animal Models
por: Sun, Chunyun, et al.
Publicado: (2023)

An Algae-Made RBD from SARS-CoV-2 Is Immunogenic in Mice
por: Govea-Alonso, Dania O., et al.
Publicado: (2022)

α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants
por: Zou, Jintao, et al.
Publicado: (2021)

Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults
por: Pasquevich, Karina A., et al.
Publicado: (2023)

Implications of conformational flexibility, lipid binding, and regulatory domains in cell-traversal protein CelTOS for apicomplexan migration
por: Kumar, Hirdesh, et al.
Publicado: (2022)

Multiepitope Proteins for the Differential Detection of IgG Antibodies against RBD of the Spike Protein and Non-RBD Regions of SARS-CoV-2
por: Gomes, Larissa R., et al.
Publicado: (2021)

Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates
Publicado: (1980)

Recombinant expression of SARS-CoV-2 receptor binding domain (RBD) in Escherichia coli and its immunogenicity in mice
por: Rahbar, Zahra, et al.
Publicado: (2022)

Impact of SARS-CoV-2 RBD Mutations on the Production of a Recombinant RBD Fusion Protein in Mammalian Cells
por: Gerez, Guillaume, et al.
Publicado: (2022)

Physical-chemical measurement method development for self-assembled, core-shell nanoparticles
por: Farkas, Natalia, et al.
Publicado: (2019)

Bacillus subtilis spores displaying RBD domain of SARS-CoV-2 spike protein
por: Vetráková, A., et al.
Publicado: (2023)

Conjugated Protein Domains as Engineered Scaffold Proteins
por: Lemmens, Lenne J. M., et al.
Publicado: (2020)

A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452
por: Feitsma, Eline A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_30ugve5d1b59bmk1o6f0bimau1